| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
42,490,000 |
| Market
Cap: |
50.99(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.2 - $3.35 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Cellectis is a clinical stage biotechnological company. Co. is developing a series of product candidates for hematologic cancers. Co.'s primary immuno-oncology product candidates, which it refers to as Universal Chimeric Antigen Receptor T-cells, are allogeneic CAR T-cells engineered to be used as an off-the-shelf treatment. UCART is a therapeutic product line that it is developing with its gene-editing platform to address unmet medical needs in oncology. Co. is focusing its initial internal pipeline in the hematologic cancer space, targeting diseases such as Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma and other types of cancers.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
0.06 (4.76%) 
